The study presents an innovative therapy to address metastatic endometrial cancer. Bradford Hill’s participation in the 2024 ASCO World Congress represents a significant milestone for oncology research in Chile and highlights the potential for international collaboration to address cancer challenges around the world.
Chilean oncologist Carlos Rojas, executive director of the Bradford Hill Clinical Research Center, marked a milestone in oncological research in Chile by presenting an innovative therapy to address cancer at the World Congress of the American Society of Clinical Oncology (ASCO) 2024. of metastatic endometrium. This event, which took place this Sunday in Chicago, brought together nearly 50,000 attendees and is recognized for presenting scientific findings and clinical studies that have the potential to transform cancer treatment worldwide.
On the occasion, the specialist presented an innovative study on the combination of two immunotherapy drugs for the treatment of metastatic endometrial cancer. Preliminary results from this study have shown a significant improvement in the tumor response of approximately 40 patients around the world who participated in the research.
“In this combination that we tested in women with endometrial cancer with a specific genetic quality, we managed to have a response where the tumors shrank significantly by a high percentage, much higher than what has normally been seen with the therapies that are currently available, so what this says is that this combination could potentially achieve better long-term results both in survival and quality of life,” highlights Dr. Rojas.
The Bradford Hill specialist emphasized the important milestone for cancer research in Chile that this presentation represents, pointing out that it is the first time that a Chilean oncologist has presented in the plenary session of the most important oncology congress in the world. ““This milestone underscores the potential for international collaboration to address the challenges of cancer and improve available treatments,” he said.
Advertisements
In addition, the specialist announced that they will most likely continue to compare this combination of immunotherapy with current standard treatments in subsequent studies. “Our goal is to demonstrate that this combination can offer greater benefits, thus establishing a new standard in the treatment of endometrial cancer,” he added.
The ASCO World Congress is a crucial platform where the latest advances in oncology are presented and discussed, and Dr. Rojas’ participation highlights the growing impact of Chilean research on the global stage.
